DA32 Life Science Tech Acquisition Corp

DA32 Life Science Tech Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on April 16, 2021 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--DA32 Life Science Tech Acquisition Corp. (Nasdaq: DALS) today announced that its board of directors (the “Board”) has determined to redeem all of its outstanding shares of Class A common stock (the “Public Shares”), effective as of July 28, 2023, because the Company will not consummate an initial business combination within the time period required by its amended and restated certificate of incorporation. As of the close of business on July 28, 2023, the Public Shares.

DA32 Life Science Tech Acquisition Corp. Announces Redemption of Shares

NEW YORK--(BUSINESS WIRE)--DA32 Life Science Tech Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 20,000,000 shares of Class A common stock at a price of $10.00 per share. The Class A common stock are expected to be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol "DALS" beginning on July 28, 2021. The offering is expected to close on July 30, 2021. The Company, sponsored by affiliates of Deerfield Management Compan

DA32 Life Science Tech Acquisition Corp., Sponsored by Deerfield, Arch Venture Partners and Section 32, Announces Pricing of $200 Million Initial Public Offering

News for DA32 Life Science Tech Acquisition Corp Stock (DALS)